Precision Oncology
About Precision Oncology
Precision oncology matches treatment to the genetic and molecular features of each patient's cancer. By testing tumours for specific changes, doctors can choose therapies more likely to work and avoid those that will not.
The Precision Oncology session at Cancer Research 2027 covers tumour profiling, targeted therapies and biomarkers. It links closely with cancer pathophysiology, which explains the molecular changes these treatments target.
Precision oncology looks for specific changes in a patient's tumour, such as gene mutations or protein markers. These changes can show which drugs are most likely to work. Testing is now done on tissue and, increasingly, on blood samples. Results are often discussed by expert teams who decide the best treatment plan.
Key Topics in Precision Oncology
• Tumour genomic profiling
• Targeted therapies and driver mutations
• Biomarkers for immunotherapy
• Liquid biopsy and circulating tumour DNA
• Molecular tumour boards
• Hereditary cancer testing
• Tumour-agnostic treatments
• Treatment resistance
• Access to precision oncology in Asia
• Health economics of genomic testing
Recent Advances in Precision Oncology
Comprehensive tumour profiling is now standard for many cancers, and tumour-agnostic drugs are approved based on genetic changes rather than cancer site. Liquid biopsy is making testing easier, linking with cancer detection and diagnosis.
AI tools are also helping interpret complex genomic data. Targeted drugs are a growing share of treatments of cancer, and their cost and access are discussed in cancer drugs market.
The number of targeted drugs and approved biomarker tests is growing every year. Blood-based tests are making it easier to check for changes during treatment. Researchers are studying why tumours become resistant and how to stay one step ahead. A key challenge now is making testing and treatment available to all patients who could benefit.
Who Should Attend the Precision Oncology Session
• Medical oncologists and haemato-oncologists
• Molecular pathologists and cancer geneticists
• Translational researchers
• Genetic counsellors
• PhD students and early-career researchers
• Oncology diagnostics and pharma teams
Why Present Your Research in Precision Oncology
Cancer Research 2027 brings precision oncology researchers together with clinicians from many health systems. You can share results and connect with colleagues in pediatric oncology applying precision approaches to childhood cancer. Teams from many countries share how they run testing and tumour boards. Presenting here helps spread good practice in precision cancer care.
Frequently Asked Questions
Can I present molecular tumour board cases?
Yes. Case studies and case series from tumour boards are welcome.
Does this session cover liquid biopsy?
Yes. Liquid biopsy and ctDNA testing are key topics.
When is Cancer Research 2027?
Cancer Research 2027 runs from 8 to 10 March 2027 at Village Hotel Changi, Singapore, and online.